Newcastle disease virus: a promising agent for tumour immunotherapy
/in International Publications, Newcastle Disease VirusHeat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
/in Hyperthermia, International Publications, Pancreatic CancerReduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
/in Breast Cancer, International Publications, Newcastle Disease VirusEffect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
/in Colorectal Cancer, Hyperthermia, International PublicationsPhase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
/in Hyperthermia, International Publications, Pancreatic CancerCell-type-specific innate immune response to oncolytic Newcastle disease virus
/in International Publications, Newcastle Disease VirusSuccessful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
/in Hyperthermia, International Publications, NSCLCDendritic cell engineering for tumor immunotherapy: from biology to clinical translation
/in Dendritic Cells, International PublicationsRecent clinical experience with oncolytic viruses
/in International Publications, Newcastle Disease VirusIMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer